Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer

Lung Cancer

Volumn 85, Issue 1, 2014, Pages 88-93

  Kim, Eric S ^a,b   Tang, XiMing ^b   Peterson, Derick R ^c   Kilari, Deepak ^a   Chow, Chi Wan ^b   Fujimoto, Junya ^b   Kalhor, Neda ^b   Swisher, Stephen G ^b   Stewart, David J ^b,d   Wistuba, Ignacio I ^b   Siddik, Zahid H ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Copper transporter; CTR1; Drug delivery; Drug resistance; Drug transport; Non small cell lung cancer; Platinum resistance; Transporter

Indexed keywords

CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; COPPER; COPPER TRANSPORTER 1; PARAFFIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; CATION TRANSPORT PROTEIN; SLC31A1 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER PATIENT; CANCER SIZE; CANCER TISSUE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; LUNG; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AFRICAN AMERICANS; AGED; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CATION TRANSPORT PROTEINS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; TUMOR BURDEN;

EID: 84901624214     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.04.005     Document Type: Article

References (31)

1. Hoang T., Xu R., Schiller J.H., et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005, 23:175-183.
2. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
3. Stewart D.J. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010, 75:173-234.
4. Gately D.P., Howell S.B. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993, 67:1171-1176.
5. Andrews P.A., Howell S.B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990, 2:35-43.
6. Shellard S.A., Fichtinger-Schepman A.M., Lazo J.S., et al. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 1993, 4:491-500.
7. Shimura M., Saito A., Matsuyama S., et al. Element array by scanning X-ray fluorescence microscopy after cis-diamminedichloro-platinum(II) treatment. Cancer Res 2005, 65:4998-5002.
8. Kawai H., Kiura K., Tabata M., et al. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 2002, 35:305-314.
9. Matsumura T., Takigawa N., Kiura K., et al. Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity. In Vivo 2005, 19:717-721.
10. Bungo M., Fujiwara Y., Kasahara K., et al. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res 1990, 50:2549-2553.
11. Kim E.S., Lee J.J., He G., et al. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 2012, 30:3345-3352.
12. Ishida S., Lee J., Thiele D.J., et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002, 99:14298-14302.
13. Song I.S., Savaraj N., Siddik Z.H., et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004, 3:1543-1549.
14. Ishida S., McCormick F., Smith-McCune K., et al. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17:574-583.
15. Chen H.H., Yan J.J., Chen W.C., et al. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 2012, 75:228-234.
16. Pataer A., Kalhor N., Correa A.M., et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 2012, 7:825-832.
17. Holzer A.K., Varki N.M., Le Q.T., et al. Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem 2006, 54:1041-1049.
18. More S.S., Akil O., Ianculescu A.G., et al. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 2010, 30:9500-9509.
19. Jandial D.D., Farshchi-Heydari S., Larson C.A., et al. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 2009, 15:553-560.
20. Siddik Z.H., Boxall F.E., Harrap K.R. Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem 1987, 163:21-26.
21. Verschraegen C.F., Kumagai S., Davidson R., et al. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R,R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol 2003, 129:549-555.
22. Tan X.L., Moyer A.M., Fridley B.L., et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2011, 17:5801-5811.
23. O'Donnell P.H., Dolan M.E. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009, 15:4806-4814.
24. Mitsudomi T., Kosaka T., Endoh H., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
25. Takano T., Ohe Y., Sakamoto H., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-6837.
26. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
27. Xie H.G., Kim R.B., Wood A.J., et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001, 41:815-850.
28. Kim R.B., Leake B.F., Choo E.F., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001, 70:189-199.
29. U.S.National Institutes of Health National Cancer Institute: SEER Cancer Statistics Review 1973-2006.
30. Moore D.H., Tian C., Monk B.J., et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010, 116:44-49.
31. Holzer A.K., Howell S.B. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 2006, 66:10944-10952.